MX2019006449A - Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). - Google Patents

Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).

Info

Publication number
MX2019006449A
MX2019006449A MX2019006449A MX2019006449A MX2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A
Authority
MX
Mexico
Prior art keywords
tricyclic heterocycle
heterocycle compounds
compounds useful
hiv integrase
integrase inhibitors
Prior art date
Application number
MX2019006449A
Other languages
English (en)
Inventor
Yu Tao
T Waddell Sherman
H Graham Thomas
A Mccauley John
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019006449A publication Critical patent/MX2019006449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente invención se refiere a compuestos heterocíclicos tricíclicos de fórmula (I), y sales o profármacos farmacéuticamente aceptables de los mismos, en donde A, X, Y, Z, R1, R7A, R7B y R8 son como se define en la presente. La presente invención también se refiere a composiciones que comprenden por lo menos un compuesto heterocíclico tricíclico, y métodos de uso de los compuestos heterocíclicos tricíclicos para el tratamiento o prevención de una infección de VIH en un sujeto. (ver Fórmula).
MX2019006449A 2016-12-02 2017-12-01 Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). MX2019006449A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662429376P 2016-12-02 2016-12-02
PCT/US2017/064116 WO2018102634A1 (en) 2016-12-02 2017-12-01 Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
MX2019006449A true MX2019006449A (es) 2019-09-10

Family

ID=62242756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006449A MX2019006449A (es) 2016-12-02 2017-12-01 Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).

Country Status (11)

Country Link
US (1) US10934312B2 (es)
EP (1) EP3548031B1 (es)
JP (1) JP2020500866A (es)
KR (1) KR20190086017A (es)
CN (1) CN110062627A (es)
AU (1) AU2017367714B2 (es)
BR (1) BR112019011074B1 (es)
CA (1) CA3042314A1 (es)
MX (1) MX2019006449A (es)
RU (1) RU2749043C2 (es)
WO (1) WO2018102634A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210477A1 (es) 2018-05-31 2021-03-11 Shionogi & Co Derivado policiclico de carbamoilpiridona
MA52802A (fr) 2018-05-31 2021-04-14 Shionogi & Co Dérivé de pyridone polycyclique
WO2019236396A1 (en) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
MX2021011394A (es) 2019-03-22 2021-10-13 Gilead Sciences Inc Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN112047945B (zh) * 2020-09-10 2021-11-12 浙江大学 螺环吡啶酮衍生物及应用
EP4196479B1 (en) 2021-01-19 2023-11-01 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042894A1 (en) 2001-08-10 2016-07-13 Shionogi & Co., Ltd. Antiviral agent
DK1441735T3 (da) 2001-10-26 2006-06-12 Angeletti P Ist Richerche Bio N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
CA2481449A1 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
AU2003292437A1 (en) 2002-12-27 2004-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CA2600832C (en) 2005-03-31 2011-12-13 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
KR101848819B1 (ko) 2005-04-28 2018-04-16 비이브 헬쓰케어 컴퍼니 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
ES2569357T3 (es) * 2005-10-27 2016-05-10 Shionogi & Co., Ltd. Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora sobre integrasa de HIV
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007143446A1 (en) 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
CN102574854B (zh) 2009-10-13 2014-04-16 伊兰科动物健康爱尔兰有限公司 大环整合酶抑制剂
US8716293B2 (en) 2010-04-02 2014-05-06 Janssen R&D Ireland Macrocyclic integrase inhibitors
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
SI2997033T1 (en) * 2013-05-17 2018-04-30 Merck Sharp & Dohme Corp. FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015174511A1 (ja) 2014-05-16 2015-11-19 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
WO2016187788A1 (en) * 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Also Published As

Publication number Publication date
EP3548031A4 (en) 2020-06-03
BR112019011074B1 (pt) 2021-01-19
JP2020500866A (ja) 2020-01-16
AU2017367714B2 (en) 2020-11-12
WO2018102634A1 (en) 2018-06-07
US10934312B2 (en) 2021-03-02
AU2017367714A1 (en) 2019-05-16
CA3042314A1 (en) 2018-06-07
CN110062627A (zh) 2019-07-26
RU2749043C2 (ru) 2021-06-03
EP3548031B1 (en) 2023-07-19
RU2019116590A (ru) 2021-01-11
EP3548031A1 (en) 2019-10-09
BR112019011074A2 (pt) 2019-08-20
KR20190086017A (ko) 2019-07-19
RU2019116590A3 (es) 2021-01-26
US20200017524A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2019006449A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12015500764B1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
NZ703064A (en) Inhibitors of hepatitis c virus
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
DK2997033T3 (da) Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere
WO2014172188A3 (en) 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
WO2020096916A3 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
GEP20196952B (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors